Compare AbbVie Inc (ABBV) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Merck & Co., Inc. — how do they compare? AbbVie Inc trades at $253.67 (market cap $449.91B), while Merck & Co., Inc. trades at $126.57 (market cap $318.26B). The key difference: AbbVie Inc is the larger of the two by market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MRK | |
|---|---|---|
Market Cap | $449.91B | $318.26B |
Sector | Health | Health |
52-Week High | $261.07 | $129.52 |
52-Week Low | $184.85 | $77.60 |
Enterprise Value | $513.38B | $361.68B |
Dividend Yield | 2.72% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Merck (MRK) trades at $126.61, down slightly by 0.13% today, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported solid earnings beats in recent quarters, with Q1 2026 loss narrower than expected, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The stock offers upside to the consensus price target of $139.33, driven by earnings momentum and expansion in high-margin drugs, but faces risks from patent expirations, regulatory scrutiny, and integration challenges from acquisitions. Investors should weigh the strong analyst buy rating (67.57%) against potential volatility from macroeconomic and industry-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
